Aspire Biopharma Holdings (ASBP) Net Cash Flow Growth (1y) (2023 - 2026)
Aspire Biopharma Holdings (ASBP) Net Cash Flow Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | - |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 53.46% |
| 10 | Aspire Biopharma Holdings | 1.09 Mn | -736,215.39 | 5,750.00 | 261.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 261.39% |
| Dec 31, 2025 | -7,216.14% |
| Sep 30, 2025 | 56,973.59% |
| Jun 30, 2025 | -4,019.17% |
| Mar 31, 2025 | 3,618.63% |
| Dec 31, 2024 | -4,510.00% |
| Sep 30, 2024 | 97.55% |
| Jun 30, 2024 | 85.43% |
| Mar 31, 2024 | 119.83% |
| Dec 31, 2023 | 99.22% |
| Sep 30, 2023 | -167.94% |
| Jun 30, 2023 | -395.04% |
| Mar 31, 2023 | -129.46% |